Total Payments
$3,300
2024 Payments
$260.98
Companies
20
Transactions
66
Medicare Patients
1,645
Medicare Billing
$233,288
Payment Breakdown by Category
Food & Beverage$2,976 (90.2%)
Education$324.35 (9.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,976 | 55 | 90.2% |
| Education | $324.35 | 11 | 9.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $573.49 | 12 | $0 (2018) |
| Allergan Inc. | $490.62 | 14 | $0 (2018) |
| ViiV Healthcare Company | $372.33 | 9 | $0 (2024) |
| Astellas Pharma US Inc | $346.98 | 4 | $0 (2019) |
| Ferring Pharmaceuticals Inc. | $333.25 | 3 | $0 (2024) |
| Gilead Sciences, Inc. | $195.98 | 5 | $0 (2019) |
| Melinta Therapeutics, Inc. | $152.99 | 2 | $0 (2018) |
| PFIZER INC. | $129.32 | 2 | $0 (2017) |
| Cumberland Pharmaceuticals, Inc. | $124.99 | 1 | $0 (2018) |
| Paratek Pharmaceuticals, Inc. | $110.06 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $260.98 | 4 | Ferring Pharmaceuticals Inc. ($210.69) |
| 2023 | $38.78 | 2 | ViiV Healthcare Company ($22.54) |
| 2022 | $290.04 | 4 | Ferring Pharmaceuticals Inc. ($122.56) |
| 2021 | $75.60 | 3 | Insmed, Inc. ($47.73) |
| 2020 | $39.25 | 2 | ViiV Healthcare Company ($23.01) |
| 2019 | $469.56 | 9 | Astellas Pharma US Inc ($161.99) |
| 2018 | $962.03 | 16 | Merck Sharp & Dohme Corporation ($382.64) |
| 2017 | $1,164 | 26 | Allergan Inc. ($429.70) |
All Payment Transactions
66 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/18/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $99.44 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/17/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $111.25 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/26/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $24.83 | General |
| Category: HIV | ||||||
| 04/16/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $25.46 | General |
| Category: HIV | ||||||
| 02/14/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: HIV | ||||||
| 01/18/2023 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 10/20/2022 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $122.56 | General |
| 05/06/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $27.48 | General |
| Category: HIV | ||||||
| 03/21/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $110.06 | General |
| Category: ANTIBIOTIC | ||||||
| 01/24/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $29.94 | General |
| Category: HIV | ||||||
| 12/13/2021 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $31.49 | General |
| Category: Respiratory | ||||||
| 03/01/2021 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $27.87 | General |
| Category: HIV | ||||||
| 01/08/2021 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 10/19/2020 | Insmed, Inc. | — | Education | In-kind items and services | $16.24 | General |
| 10/01/2020 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: HIV | ||||||
| 12/11/2019 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $101.20 | General |
| Category: HIV | ||||||
| 08/23/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.46 | General |
| 08/09/2019 | TETRAPHASE PHARMACEUTICALS, INC. | Xerava (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: Complicated Intra-Abdominal Infections | ||||||
| 06/26/2019 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $120.51 | General |
| Category: HIV | ||||||
| 05/23/2019 | AngioDynamics, Inc. | — | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: VIT | ||||||
| 04/08/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $89.99 | General |
| 04/08/2019 | Astellas Pharma US Inc | — | Education | In-kind items and services | $72.00 | General |
| 03/28/2019 | Osiris Therapeutics Inc. | Stravix (Biological), Grafix, GrafixPL | Food and Beverage | In-kind items and services | $11.59 | General |
| Category: Other Advanced Wound Management | ||||||
| 02/27/2019 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: Hepatitis B Vaccine | ||||||
| 12/13/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $7.15 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 353 | 664 | $235,317 | $62,617 |
| 2022 | 4 | 321 | 495 | $168,626 | $43,056 |
| 2021 | 5 | 430 | 643 | $221,522 | $57,871 |
| 2020 | 6 | 541 | 781 | $266,367 | $69,744 |
Total Patients
1,645
Total Services
2,583
Medicare Billing
$233,288
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 115 | 286 | $94,022 | $26,872 | 28.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 109 | 120 | $70,885 | $16,046 | 22.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 83 | 184 | $41,082 | $11,477 | 27.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 15 | 27 | $12,681 | $3,495 | 27.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 35 | $11,682 | $3,486 | 29.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $4,965 | $1,239 | 25.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 120 | 231 | $73,689 | $18,659 | 25.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 81 | 85 | $52,700 | $13,256 | 25.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 103 | 153 | $33,813 | $8,656 | 25.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 17 | 26 | $8,424 | $2,486 | 29.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 143 | 266 | $84,854 | $21,976 | 25.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 112 | 113 | $70,060 | $18,123 | 25.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 129 | 208 | $45,968 | $12,075 | 26.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 25 | 26 | $10,920 | $2,849 | 26.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 21 | 30 | $9,720 | $2,847 | 29.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 128 | 132 | $81,840 | $21,577 | 26.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 138 | 246 | $78,474 | $20,807 | 26.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 190 | 301 | $66,521 | $17,101 | 25.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 42 | 44 | $18,480 | $4,844 | 26.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 27 | 38 | $12,312 | $3,056 | 24.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 16 | 20 | $8,740 | $2,358 | 27.0% |
About Dr. Antonio Crespo, MD
Dr. Antonio Crespo, MD is a Infectious Disease healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033185392.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Antonio Crespo, MD has received a total of $3,300 in payments from pharmaceutical and medical device companies, with $260.98 received in 2024. These payments were reported across 66 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($2,976).
As a Medicare-enrolled provider, Crespo has provided services to 1,645 Medicare beneficiaries, totaling 2,583 services with total Medicare billing of $233,288. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Orlando, FL
- Active Since 02/27/2006
- Last Updated 11/11/2016
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1033185392
Products in Payments
- AVYCAZ (Drug) $307.46
- REBYOTA (Biological) $210.69
- ZERBAXA (Drug) $204.90
- DALVANCE (Drug) $171.56
- CABENUVA (Biological) $158.12
- DIFICID (Drug) $132.43
- ELIQUIS (Drug) $129.32
- Caldolor (Drug) $124.99
- DOVATO (Drug) $124.21
- Vabomere (Drug) $122.70
- Biktarvy (Drug) $120.51
- Myrbetriq (Drug) $115.00
- NUZYRA (Drug) $110.06
- BRIDION (Drug) $103.14
- AUBAGIO (Drug) $97.49
- ZINPLAVA (Biological) $97.38
- XIFAXAN (Drug) $96.70
- VNS Therapy (Device) $92.92
- Arikayce (Drug) $63.97
- Baxdela (Drug) $30.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Orlando
Dr. Charlotte-Paige Rolle, M.d, M.D
Infectious Disease — Payments: $520,539
Infectious Disease $520,539
Federico Hinestrosa, Md, MD
Infectious Disease — Payments: $331,463
Infectious Disease $331,463
Vincent Hsu, Md, MD
Infectious Disease — Payments: $199,883
Infectious Disease $199,883
Edwin Dejesus, Md, MD
Infectious Disease — Payments: $132,951
Infectious Disease $132,951
Patricia Couto, M.d, M.D
Infectious Disease — Payments: $22,106
Infectious Disease $22,106
Dr. William Robbins, M.d, M.D
Infectious Disease — Payments: $19,785
Infectious Disease $19,785